Indication
Refractory
39 clinical trials
51 products
9 drugs
Product
SelinexorClinical trial
A Phase I Trial of Selinexor, Ruxolitinib and Methylprednisolone for Patients With Relapsed/Refractory Multiple MyelomaStatus: Not yet recruiting, Estimated PCD: 2027-04-01
Product
RuxolitinibProduct
MethylprednisoloneClinical trial
LUMT1A22, Phase 1 Study of BAFF CAR T Cells (LMY-920) for Treatment of Relapsed or Refractory Myeloma (LMY-920-002)Status: Recruiting, Estimated PCD: 2025-07-31
Clinical trial
A Phase 2 Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma Patients With t(11;14)Status: Not yet recruiting, Estimated PCD: 2026-03-31
Product
VenetoclaxClinical trial
A Phase 1 First-in-human Dose-escalation and Dose-expansion Study of BMF-219, an Oral Covalent Menin Inhibitor, in Adult Patients With Acute Leukemia (AL), Diffuse Large B-cell Lymphoma (DLBCL), Multiple Myeloma (MM), and Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL)Status: Recruiting, Estimated PCD: 2024-12-31
Product
BMF-219Clinical trial
A Phase 2b, Open-label Study of Selinexor Plus Low-dose Dexamethasone (Sd) in Patients With Penta-refractory Multiple Myeloma (MM), Selinexor and Bortezomib Plus Low-dose Dexamethasone (SVd) in Patients With Triple-class Refractory MM, and Selinexor and Pomalidomide Plus Low-dose Dexamethasone (SPd) in Patients With Relapsed Refractory MM.Status: Recruiting, Estimated PCD: 2024-06-30
Product
DexamethasoneProduct
BortezomibProduct
PomalidomideClinical trial
A Single-center, Prospective, Single-arm Clinical Study of All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma (MM)Status: Recruiting, Estimated PCD: 2025-12-31
Product
All-trans Retinoic AcidClinical trial
A Phase 1/1b, Open-Label, Multi-Center, Two-Part Study of SETD2 Inhibitor EZM0414 in Subjects With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell LymphomaStatus: Recruiting, Estimated PCD: 2024-12-30
Product
EZM0414Product
Ceramide NanoLiposomeClinical trial
Phase I Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia (RR-AML)Status: Not yet recruiting, Estimated PCD: 2024-09-01
Product
MT-601Clinical trial
A Phase 1 Study of Patient-Derived Multi-Tumor-Associated Antigen-Specific T Cells (MT-601) Administered to Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL [APOLLO])Status: Recruiting, Estimated PCD: 2028-02-28
Clinical trial
Phase I Clinical Study of CAR-T Cells (C-4-29) in the Treatment of Patients With Relapsed/Refractory Multiple MyelomaStatus: , Estimated PCD: 2023-12-31
Product
C-4-29Product
RadotinibClinical trial
A Phase 3 Multinational, Multi-center, Single-arm, Open-label Study for the Efficacy and Safety of Radotinib in Ph+ Chronic Phase Chronic Myeloid Leukemia Patients With Failure or Intolerance to Previous TKIs Therapy Including ImatinibStatus: Recruiting, Estimated PCD: 2025-01-29
Clinical trial
A Phase IV, Post Marketing, Prospective, Observational Cohort Study to Investigate Safety and Effectiveness of Alvocade® in Iranian Patients With Multiple MyelomaStatus: Completed, Estimated PCD: 2022-12-01
Product
Humanized CD19 CAR-T cellsClinical trial
Humanized Chimeric Antigen Receptor T Cells Against CD19 With Cytokine Release Syndrome (CRS) Suppression Technology for Refractory/Relapsed CD19+ Acute Lymphoblastic LeukemiaStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Multi-Institution Study of TGFβ Imprinted, Ex Vivo Expanded Universal Donor NK Cell Infusions as Adoptive Immunotherapy in Combination With Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Pediatric Bone and Soft TissueStatus: Recruiting, Estimated PCD: 2026-12-01
Clinical trial
Phase 1 Study of Lentivirally Transduced T Cells Engineered to Contain Anti-CD123 Linked to TCRζ and 4-1BB Signaling Domains in Pediatric Subjects With Refractory or Relapsed Acute Myeloid LeukemiaStatus: Active (not recruiting), Estimated PCD: 2036-01-01
Clinical trial
Abemaciclib in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma, and in Children With Recurrent and Refractory Solid Tumors Including Malignant Brain TumorsStatus: Completed, Estimated PCD: 2023-10-10
Product
AbemaciclibClinical trial
A Phase I Trial of CD19-Targeted EGFRt/19-28z/4-1BBL "Armored" Chimeric Antigen Receptor (CAR) Modified T Cells in Patients With Relapsed or Refractory CD19+ Hematologic MalignanciesStatus: Active (not recruiting), Estimated PCD: 2025-03-01
Clinical trial
A Phase 1 Open-Label, Dose Escalation Study of Pitavastatin in Combination With Venetoclax in Patients With Chronic Lymphocytic Leukemia or Acute Myeloid LeukemiaStatus: Active (not recruiting), Estimated PCD: 2023-04-06
Product
PitavastatinClinical trial
Phase II Study of Pembrolizumab in Multiple Myeloma Patients Relapsing After or Refractory to Anti-BCMA CAR-T TherapiesStatus: Terminated, Estimated PCD: 2023-12-31
Product
PembrolizumabClinical trial
A Phase I Study to Assess the Tolerability of 225Ac-DOTATATE in Patients With Refractory and Relapsing Multiple Myeloma Expressing Somatostatin ReceptorsStatus: Not yet recruiting, Estimated PCD: 2026-10-01
Product
225Ac-DOTATATEClinical trial
Study of Isatuximab Plus Pomalidomide and Dexamethasone in Highly Toxicity-vulnerable Subjects With Relapsed or Refractory Multiple MyelomaStatus: Recruiting, Estimated PCD: 2028-12-28
Product
IsatuximabClinical trial
A Phase II Study of Pembrolizumab and Entinostat in Patients With Relapsed and Refractory LymphomasStatus: Active (not recruiting), Estimated PCD: 2025-06-01
Product
EntinostatDrug
PomalidomideClinical trial
A Phase I Study of Venetoclax in Combination With Cytotoxic Chemotherapy, Including Calaspargase Pegol, for Children, Adolescents and Young Adults With High-Risk Hematologic MalignanciesStatus: Recruiting, Estimated PCD: 2025-04-02
Product
AzacitidineProduct
CytarabineProduct
MethotrexateProduct
HydrocortisoneDrug
mFOLFOX6Drug
VincristineProduct
DoxorubicinProduct
DexrazoxaneProduct
Calaspargase PegolClinical trial
Determining Safety and Maximum Tolerated Dose (MTD) of Anti-BCMA CAR-NK Therapy in Relapsed or Refractory Multiple MyelomaStatus: Not yet recruiting, Estimated PCD: 2026-04-30
Product
Anti-BCMA CAR-NKClinical trial
The Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) and CCR4 for Relapsed/Refractory CD30+ Hodgkin s LymphomaStatus: Not yet recruiting, Estimated PCD: 2026-07-01
Drug
CisplatinProduct
Cell infusionClinical trial
A Phase I Study Evaluating Allogeneic Memory T Cells Engineered to Express Chimeric Antigen Receptors Specific for CD19 for the Treatment of Pediatric and Young Adult Patients ≤ 21 Years of Age With Relapsed or Refractory CD19-Positive LeukemiaStatus: Recruiting, Estimated PCD: 2026-06-01
Product
CD19-CAR T-cellsDrug
cyclophosphamideProduct
FludarabineProduct
MesnaClinical trial
Phase I Trial to Evaluate Safety and Preliminary Efficacy of CLDN6/GPC3/Mesothelin/AXL-CAR-NK in Patients With CLDN6/GPC3/Mesothelin/AXL-positive Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
Phase 1 Study of Lentivirally Transduced T Cells Engineered to Contain Anti-CD123 Linked to TCRζ and 4-1BB Signaling Domains in Subjects With Refractory or Relapsed Acute Myeloid LeukemiaStatus: Recruiting, Estimated PCD: 2024-08-01
Product
CART123 cellsClinical trial
Clinical Study on Efficacy and Safety of GTP Regimen in the Treatment of Refractory/Recurrent Hemophagocytic LymphohistiocytosisStatus: Not yet recruiting, Estimated PCD: 2024-09-15
Product
GTPClinical trial
SJCAR19: A Phase I/II Study Evaluating SJCAR19 (CD19-Specific CAR Engineered Autologous T-Cells) in Pediatric and Young Adult Patients ≤ 21 Years of Age With Relapsed or Refractory CD19+ Acute Lymphoblastic LeukemiaStatus: Active (not recruiting), Estimated PCD: 2023-07-01
Clinical trial
A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting CAR T-cells in Patients With Relapsed and Refractory B-cell MalignanciesStatus: Recruiting, Estimated PCD: 2025-06-01
Product
MDC-CAR-BCMA001Drug
fludarabineClinical trial
Matched Targeted Therapy (MTT) Recommendation for Patients With Recurrent, Refractory, or High Risk Leukemias and Myelodysplastic SyndromeStatus: Active (not recruiting), Estimated PCD: 2022-05-16
Product
Leukemia ProfilingClinical trial
A Phase II Study of Carfilzomib, Oral Cyclophosphamide, and Dexamethasone for Relapsed and/or Refractory Multiple MyelomaStatus: Not yet recruiting, Estimated PCD: 2027-06-30
Drug
CarfilzomibClinical trial
Phase I Study of Intracranial Injection of T Cells Expressing HER2-specific Chimeric Antigen Receptors (CAR) in Subjects With HER2-Positive Tumors of the Central Nervous System (iCAR)Status: Active (not recruiting), Estimated PCD: 2022-04-27
Product
HER2-specific T cellsClinical trial
Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid LeukemiaStatus: Not yet recruiting, Estimated PCD: 2026-01-30
Clinical trial
A Single-arm, Prospective Study of Cyclosporine in Combination With Carfilzomib and Dexamethasone in Patients With Relapsed Multiple Myeloma Refractory to Carfilzomib With High Expression of the Peptidylprolyl Isomerase A (PPIA) Gene in Myeloma CellsStatus: Recruiting, Estimated PCD: 2024-04-01
Product
CyclosporineClinical trial
A Phase 2 Study With Safety Run-In of Marizomib, Pomalidomide, and Dexamethasone For Relapsed and Refractory Multiple Myeloma and CNS MyelomaStatus: Not yet recruiting, Estimated PCD: 2025-12-02
Product
MarizomibDrug
lenalidomideClinical trial
Pilot Study of IGF-Methotrexate Conjugate in the Treatment of Myelodysplastic Syndrome, CMML and Oligoblastic AMLStatus: Terminated, Estimated PCD: 2021-06-30
Product
IGF/MTXClinical trial
Targeting NUDT21 siRNA Drugs for Patients With Refractory Retinoblastoma (A Two-center Prospective Single Arm Trial)Status: Not yet recruiting, Estimated PCD: 2025-05-21
Product
NUDT21 siRNA